Department of Chemistry & Biochemistry, San Diego State University, San Diego, CA 92182-1030, USA.
Anticancer Agents Med Chem. 2011 Sep;11(7):658-68. doi: 10.2174/187152011796817691.
Extensive evidence supports involvement of electron transfer (ET), reactive oxygen species (ROS) and oxidative stress (OS) in the mechanism of many anticancer drugs. The common ET functionalities, usually present in the drug metabolites, are quinones (or precursors), metal complexes (or complexors), hydroxylamine and nitroso from ArNO2 or ArNH2, and conjugated imines (or iminium species). The ET agents function catalytically in redox cycling with formation of ROS from oxygen. Electrochemical data add support to the mechanistic viewpoint. The generated metabolites generally possess reduction potentials amenable to ET in vivo, thus giving rise to ROS. The resulting OS is a participant in destruction of the cancer cell. The action has been termed phagomimetic based on similarity to phagocytosis. It is important to recognize that drug action is often multipronged. The various modes of action are summarized.
大量证据表明,电子转移(ET)、活性氧物种(ROS)和氧化应激(OS)参与了许多抗癌药物的作用机制。常见的 ET 功能通常存在于药物代谢物中,包括醌(或前体)、金属配合物(或络合剂)、来自 ArNO2 或 ArNH2 的羟胺和亚硝胺,以及共轭亚胺(或亚胺物种)。ET 试剂在氧化还原循环中催化作用,从氧气中形成 ROS。电化学数据为该机制观点提供了支持。生成的代谢物通常具有体内 ET 的还原电位,从而产生 ROS。由此产生的 OS 是破坏癌细胞的参与者。这种作用被称为吞噬模拟,基于与吞噬作用的相似性。需要认识到的是,药物作用通常是多方面的。各种作用模式进行了总结。